Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Declines By 13.4%

BioAtla, Inc. (NASDAQ:BCAB) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 4,380,000 shares, a decrease of 13.4% from the January 15th total of 5,060,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is currently 3.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered shares of BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

BioAtla Trading Up 6.6 %

BCAB opened at $0.46 on Tuesday. BioAtla has a 1-year low of $0.38 and a 1-year high of $4.02. The company has a 50 day simple moving average of $0.66 and a two-hundred day simple moving average of $1.40.

Hedge Funds Weigh In On BioAtla

Several hedge funds have recently modified their holdings of BCAB. Magnus Financial Group LLC purchased a new position in shares of BioAtla in the fourth quarter worth $28,000. Vontobel Holding Ltd. purchased a new position in shares of BioAtla in the third quarter worth $28,000. Chicago Partners Investment Group LLC purchased a new position in shares of BioAtla in the third quarter worth $44,000. Two Sigma Investments LP lifted its holdings in shares of BioAtla by 84.0% in the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after buying an additional 61,725 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of BioAtla by 204.1% in the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after buying an additional 100,204 shares in the last quarter. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.